In other words, the price has increased by $0.0000 from its previous closing price. On the day, 14244438 shares were traded.
Ratios:
For a better understanding of CATX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.55 and its Current Ratio is at 2.67. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 06 ’24 when Lantheus Alpha Therapy, LLC bought 60,431,039 shares for $0.95 per share. The transaction valued at 57,409,487 led to the insider holds 116,773,394 shares of the business.
Williamson Robert F III bought 127,206 shares of CATX for $90,710 on Jan 30 ’24. The Director now owns 338,761 shares after completing the transaction at $0.71 per share. On Jan 29 ’24, another insider, Williamson Robert F III, who serves as the Director of the company, bought 25,266 shares for $0.64 each. As a result, the insider paid 16,170 and bolstered with 211,555 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CATX now has a Market Capitalization of 627.88M and an Enterprise Value of 613.20M. For the stock, the TTM Price-to-Sale (P/S) ratio is 71.03 while its Price-to-Book (P/B) ratio in mrq is 3.04. Its current Enterprise Value per Revenue stands at 61.64 whereas that against EBITDA is -67.62.
Stock Price History:
Over the past 52 weeks, CATX has reached a high of $1.23, while it has fallen to a 52-week low of $0.20. The 50-Day Moving Average of the stock is 0.8080, while the 200-Day Moving Average is calculated to be 0.5082.
Shares Statistics:
Over the past 3-months, CATX traded about 2.41M shares per day on average, while over the past 10 days, CATX traded about 4.69M shares per day. A total of 586.80M shares are outstanding, with a floating share count of 391.22M. Insiders hold about 33.33% of the company’s shares, while institutions hold 6.24% stake in the company. Shares short for CATX as of Feb 29, 2024 were 1.87M with a Short Ratio of 0.78, compared to 2.05M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.38% and a Short% of Float of 0.38%.
Earnings Estimates
Current recommendations for the stock of the company come from 3 analysts. On average, analysts expect EPS of -$0.04 for the current quarter, with a high estimate of -$0.03 and a low estimate of -$0.04, while EPS last year was -$0.02. The consensus estimate for the next quarter is -$0.03, with high estimates of -$0.02 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
Revenue Estimates
1 analysts predict $2.48M in revenue for the current quarter. It ranges from a high estimate of $2.48M to a low estimate of $2.48M. As of the current estimate, Perspective Therapeutics Inc’s year-ago sales were $1.83M, an estimated increase of 35.10% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $2.79M, an increase of 35.10% over than the figure of $35.10% in the same quarter last year. There is a high estimate of $2.79M for the next quarter, whereas the lowest estimate is $2.79M.
A total of 1 analysts have provided revenue estimates for CATX’s current fiscal year. The highest revenue estimate was $10.64M, while the lowest revenue estimate was $10.64M, resulting in an average revenue estimate of $10.64M. In the same quarter a year ago, actual revenue was $3.33M, up 219.50% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $11.18M in the next fiscal year. The high estimate is $11.18M and the low estimate is $11.18M. The average revenue growth estimate for next year is up 5.10% from the average revenue estimate for this year.
